More than 10% of breast biopsies performed based on findings at mammography yield
highrisk lesions (HRLs). 1 HRLs refer to a group of heterogeneous lesions that can be …

Benign breast disease is a spectrum of common disorders. The majority of patients with a
clinical breast lesion will have benign process. Management involves symptom control when …

Background Based on modern series demonstrating low upgrade rates for pure lobular
neoplasia (LN) diagnosed on core needle biopsy (CNB), our institution no longer …

Lobular neoplasia (LN) is an atypical proliferation of small, dyscohesive epithelial cells
within the terminal duct lobular unit (TDLU), with or without pagetoid extension and …

Benign and atypical lesions associated with breast cancer risk are often encountered in core
needle biopsies (CNBs) of the breast. For these lesions, the rate of “upgrade” to carcinoma …

Pathologists frequently encounter non‐malignant histological findings in percutaneous core
needle biopsies (CNB s). Standards for the management of patients with lesions such as …

This review reflects a collaboration between the American Registry of Pathology (the
publisher of the Armed Forces Institute of Pathology Fascicles) and Annals of Diagnostic …

Benign breast diseases, which are commonly seen in clinical practice, have various clinical
presentations and implications, as well as management strategies. This article describes …

Atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS) are nonmalignant breast
lesions that confer a 4-to 10-fold increased risk for breast cancer in women. Often, AH and …

Lobular neoplasia (LN) is a term that describes the continuum of atypical epithelial lesions
originating in the terminal duct-lobular unit (TDLU) of the breast. 1 To predict cancer risk …